EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multifunctional molecular hybrid for targeted colorectal cancer cells: Integrating doxorubicin, AS1411 aptamer, and T9/U4 ASO

Kanpitcha Jiramitmongkon, Pichayanoot Rotkrua, Paisan Khanchaitit, Jiraporn Arunpanichlert, Boonchoy Soontornworajit iD

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0317559 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Kanpitcha Jiramitmongkon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science and Technology, Department of Chemistry, Thammasat University, Pathumthani, Thailand. Hauptthemen laut MEDLINE: Doxorubicin, Aptamers, Nucleotide, Oligodeoxyribonucleotides, Colorectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Office of the Permanent Secretary, Ministry of Higher Education, Science, Research and Innovation, Thailand, Thammasat University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) poses a global health challenge, with current treatments often harming both cancerous and normal cells. To improve efficacy, a multifunctional drug delivery platform has been developed, integrating bioactive materials, anticancer agents, and targeted recognition ligands into a single molecule. This study aimed to create a molecular hybrid (MH) containing doxorubicin, AS1411 aptamer, and T9/U4 ASO to regulate SW480 cell proliferation. The AS1411 aptamer targets nucleolin, overexpressed on cancer cell membranes, while T9/U4 ASO inhibits human telomerase RNA activity, further hindering cancer cell proliferation. AS-T9/U4_MH was synthesized via oligonucleotide hybridization, followed by doxorubicin loading and evaluation of its impact on cell proliferation. Binding capability of this MH was verified using fluorescence microscopy and flow cytometry, demonstrating specific recognition of SW480 cells due to nucleolin availability on the cell surface. These findings were corroborated by both microscopy and flow cytometry. AS-T9/U4_MH exhibited anti-proliferative effects, with the doxorubicin-loaded system demonstrating encapsulation and reduced toxicity. Moreover, the presence of Dox within AS-T9/U4_MH led to a notable reduction in hTERT and vimentin expression in SW480 cells. Additionally, examination of apoptotic pathways unveiled a marked decrease in Bcl-2 expression and a simultaneous increase in Bax expression in SW480 cells treated with Dox-loaded AS-T9/U4_MH, indicating its impact on promoting apoptosis. This molecular hybrid shows promise as a platform for integrating chemotherapeutic drugs with bioactive materials for cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinAptamers, NucleotideOligodeoxyribonucleotidesColorectal NeoplasmsOligonucleotides, AntisenseHumansCell ProliferationCell Line, TumorNucleolinTelomeraseRNA-Binding ProteinsApoptosisPhosphoproteinsDrug Delivery SystemsAntibiotics, Antineoplastic

Substanzen

DoxorubicinAptamers, NucleotideOligodeoxyribonucleotidesAGRO 100NucleolinTelomeraseRNA-Binding ProteinsPhosphoproteinsOligonucleotides, AntisenseAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Faculty of Science and Technology, Department of Chemistry, Thammasat University, Pathumthani, Thailand.
  • National Nanotechnology Center, National Science and Technology Development Agency, Thailand Science Park, Pathumthani, Thailand.
  • Thammasat University Research Unit in Innovation of Molecular Hybrid for Biomedical Application, Pathumthani, Thailand.
  • Faculty of Medicine, Department of Preclinical Science, Division of Biochemistry, Thammasat University, Pathumthani, Thailand.

ORCID-Profile: Boonchoy Soontornworajit

Förderung

  • Office of the Permanent Secretary, Ministry of Higher Education, Science, Research and Innovation, Thailand
  • Thammasat University

Zitieren

APA

Jiramitmongkon, K., Rotkrua, P., Khanchaitit, P., Arunpanichlert, J., & Soontornworajit, B. (2025). Multifunctional molecular hybrid for targeted colorectal cancer cells: Integrating doxorubicin, AS1411 aptamer, and T9/U4 ASO. PLOS ONE. https://doi.org/10.1371/journal.pone.0317559

Vancouver

Jiramitmongkon K, Rotkrua P, Khanchaitit P, Arunpanichlert J, Soontornworajit B. Multifunctional molecular hybrid for targeted colorectal cancer cells: Integrating doxorubicin, AS1411 aptamer, and T9/U4 ASO. PLOS ONE. 2025. doi:10.1371/journal.pone.0317559

BibTeX
@article{Jiramitmongkon2025,
  author = {Jiramitmongkon, Kanpitcha and Rotkrua, Pichayanoot and Khanchaitit, Paisan and Arunpanichlert, Jiraporn and Soontornworajit, Boonchoy},
  title = {Multifunctional molecular hybrid for targeted colorectal cancer cells: Integrating doxorubicin, AS1411 aptamer, and T9/U4 ASO},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0317559}
}
Kostenlos starten →